COLOSSAL BIOSCIENCES TARGETS $20B–$30B VALUATION

The funding round would represent significant growth for the biotech firm, which uses genetic engineering and synthetic biology to resurrect extinct species. Colossal has previously focused on reviving woolly mammoths and Tasmanian tigers through advanced biotechnology. The reported valuation increase reflects growing investor interest in de-extinction and synthetic biology sectors. Colossal has secured previous funding from notable backers, including venture capital firms and tech entrepreneurs. The company's technology aims to restore extinct species by editing the genomes of living relatives. If successful, the approach could have applications beyond de-extinction, including conservation efforts for endangered species and development of disease-resistant organisms. Details on the timing of the funding round and lead investors have not been disclosed. The startup continues to advance its core projects while exploring the commercial and scientific potential of its platform.